NCT00991107View on ClinicalTrials.gov

A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Insulin Resistance
Interventions
DRUG

HE3286

HE3286 20 mg (10 mg BID) for 28 days

Trial Locations (1)

70808

Clinical Site, Baton Rouge

Sponsors
All Listed Sponsors
lead

Harbor Therapeutics

INDUSTRY